Shares of AstraZeneca AZN rose 0.9% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 20% year over year to $0.54, which missed the estimate of $0.68.
Revenue of $7,410,000,000 up by 11.19% year over year, which beat the estimate of $6,970,000,000.
Looking Ahead
The upcoming fiscal year's EPS expected to be between $2.38 and $2.50.
AstraZeneca hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Feb 11, 2021
Time: 06:45 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/2zfjjnc3
Technicals
Company's 52-week high was at $64.94
52-week low: $36.15
Price action over last quarter: down 9.19%
Company Description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
